Josep-Maria Ribera

Overview

Best Publications

• Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

  Hagop M Kantarjian;Anthony Stein;Nicola Gökbuget;Adele K. Fielding

  1813
  Citations

• Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

  Max S. Topp;Nicola Gökbuget;Anthony S. Stein;Gerhard Zugmaier

  1284
  Citations

• Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

  María-Victoria Mateos;Albert Oriol;Joaquín Martínez-López;Norma Gutiérrez

  620
  Citations

• Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors.

  Bosch F;López-Guillermo A;Campo E;Ribera Jm

  453
  Citations

• Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008

  M. Bruggemann;A. Schrauder;T. Raff;H. Pfeifer

  447
  Citations

• High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA

  Joan Bladé;Laura Rosiñol;Ana Sureda;Josep M. Ribera

  440
  Citations

• Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.

  Miguel A. Sanz;Pau Montesinos;Chelo Rayón;Alexandra Holowiecka

  412
  Citations

• Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification

  A. López-Guillermo;J. Cid;A. Salar;A. López

  403
  Citations

• Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival

  Juan José Lahuerta;Maria Victoria Mateos;Joaquin Martínez-López;Laura Rosiñol

  395
  Citations

• Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

  D. Hoelzer;R. Bassan;H. Dombret;A. Fielding

  395
  Citations

• Comparison of the Results of the Treatment of Adolescents and Young Adults With Standard-Risk Acute Lymphoblastic Leukemia With the Programa Español de Tratamiento en Hematología Pediatric-Based Protocol ALL-96

  Josep-María Ribera;Albert Oriol;Miguel-Angel Sanz;Mar Tormo

  337
  Citations

• Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy.

  Marta Pratcorona;Salut Brunet;Josep Nomdedéu;Josep Maria Ribera

  334
  Citations

• Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group

  Albert Oriol;Susana Vives;Jesús-María Hernández-Rivas;Mar Tormo

  312
  Citations

• Treatment of High-Risk Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial

  Josep-Maria Ribera;Albert Oriol;Mireia Morgades;Pau Montesinos

  305
  Citations

• Sustained Remissions of High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome After Reduced-Intensity Conditioning Allogeneic Hematopoietic Transplantation: Chronic Graft-Versus-Host Disease Is the Strongest Factor Improving Survival

  David Valcárcel;Rodrigo Martino;Dolores Caballero;Jesus Martin

  302
  Citations

• Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes

  Francesc Solé;Elisa Luño;Carmen Sanzo;Blanca Espinet

  299
  Citations

• Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL

  Philippe Rousselot;Marie Magdelaine Coudé;Nicola Gokbuget;Carlo Gambacorti Passerini

  288
  Citations

• Effect of using reporting guidelines during peer review on quality of final manuscripts submitted to a biomedical journal: masked randomised trial.

  E Cobo;J Cortés;J M Ribera;F Cardellach

  275
  Citations

• Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/ Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

  Anna Sureda;Carme Canals;Reyes Arranz;Dolores Caballero

  261
  Citations

• Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

  María-Victoria Mateos;Albert Oriol;Joaquín Martínez-López;Norma Gutiérrez

  188
  Citations